Esmolol hydrochloride is under clinical development by NovaLead Pharma and currently in Phase III for Diabetic Foot Ulcers. According to GlobalData, Phase III drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Esmolol hydrochloride LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Esmolol hydrochloride overview
Esmolol hydrochloride (Galnobax) is under development for the treatment of diabetic foot ulcer. The therapeutic candidate is applied topically and formulated as gel. The drug candidate has nitric oxide (NO)-potentiating activity. It is developed based on Reverse Virtual High Throughput Screening (RVHTS) platform.
NovaLead Pharma overview
NovaLead Pharma is a drug discovery company focused on the development of generic drugs. The company’s pipeline products include Galnobax, a topical gel for treating diabetic foot ulcers; and NLP91, being developed as a generic drug molecule against skin diseases such as psoriasis and dermatitis. It also discovers and provides novel indications of existing drugs through reverse virtual high throughput screening technology. NovaLead Pharma seeks to work in collaborations with other pharmaceutical companies for licensing opportunities in Europe, Japan and other regulated markets. The company operates in India and the US. NovaLead Pharma is headquartered in Pune, Maharashtra, India.
For a complete picture of Esmolol hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
